A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Summary

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Moderate-to-Severe Atopic Dermatitis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

12 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Nektar Therapeutics

Last updated on ClinicalTrials.gov

September 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites